CMN-005 is under clinical development by CoImmune and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.
According to GlobalData, the latest event to affect CMN-005’s likelihood of approval (LoA) and phase transition for B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia) took place on 19 Mar 2022, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway and decreased the likelihood of final approval for this indication.
GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their CMN-005 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.
CMN-005 overview
CMN-005 is under development for the treatment of relapsed and refractory B-cell acute lymphocytic leukemia, chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma post bone marrow transplantation. It constitutes of Chimeric Antigen Receptor (CAR) modified Cytokine Induced Killer (C.I.K.) cells. It acts by targeting the cancer cells which express CD19 antigen. The cell therapy is developed based on C.I.K. CAR technology that utilizes SB100X transposase, a component of the non-viral, Sleeping Beauty transposon-based gene transfer system. It is administered through intravenous route.
CoImmune overview
CoImmune is a biopharmaceutical company that carries out the development and manufacture of immunotherapies to treat cancer, inflammatory and autoimmune diseases. Its clinical products pipeline includes CARCIK-CD19 (CMN-005), CAR-CIK (CMN-006), CAR-CIK solid tumors, and CMN-001. The comnpany’s products are used in the treatment of acute lymphoblastic leukemia, non-hodgkin’s lymphoma, chronic lymphocytic leukemia, acute myeloid leukemia, and metastatic renal cell carcinoma, among others. It also carries out the research and development activities through its cell therapy technology platforms which include allogeneic cytokine-induced killer (CIK) and autologous RNA-loaded dendritic cells. CoImmune is headquartered in Durham, North Carolina, the US.
Quick View CMN-005 LOA Data
Report Segments |
|
Drug Name |
|
Administration Pathway |
|
Therapeutic Areas |
|
Key Developers |
|
Highest Development Stage |
|